Interferon regulatory factor-1 (IRF-1) is a transcriptional inducer of the interferon-␤ (IFN-␤) gene and other interferonstimulated genes. A GT repeat polymorphism in the 7th intron of the IRF-1 gene was used as a marker to test for association with multiple sclerosis (MS) in a case-control study including individuals from Germany, Northern Italy and Sweden. In none of these populations, did we find any significant allelic association with disease. This lack of association was confirmed by testing transmission disequilibrium of individual IRF1 alleles in a representative sample of Sardinian simplex MS families. No deviation of the expected 50% transmission rates was seen. Therefore, our work does not provide evidence in favor of IRF1 being a candidate for conferring genetic susceptibility to, or protection against, MS in Europe. Genes and Immunity (2000) 1, 290-292.
Multiple sclerosis (MS) is a polygenic, autoimmune disease characterized by chronic inflammation of the white matter of the central nervous system. Because of their complex effects on the induction and maintenance of inflammatory reactions, cytokines and interferons are considered as an important class of disease-promoting or limiting effector molecules. When administered to MS patients in recombinant form, interferon-␥ (IFN-␥) and interferon-␤ (IFN-␤) in particular, are known to affect disease progression and severity in radically opposing manners. While administration of IFN-␥ leads to exacerbation of the disease, recombinant IFN-␤ reduces exacerbation rates and destruction of the central nervous system (CNS) components. 1, 2 Interferon regulatory factor-1 (IRF-1) is a transcriptional activator of the IFN-␤ gene, and is itself induced by cytokines such as IFN-␥ and IL-12. [3] [4] [5] In view of this observation the question arises whether IRF-1 may act in MS as an endogenous '(un)coupler' of destructive, Th1-mediated (IFN-␥, IL-12) and protective (IFN-␤) responses. A possibly more complex role for IRF-1 in the pathogenesis of CNS inflammation is highlighted by research on an experimental autoimmune encephalomyelitis (EAE) model for MS. Here, in mice lacking the IRF-1 gene, the incidence of EAE was decreased compared to IRF-1 (+/−) mice. 6 The IRF-1 gene has been assigned to human chromosome 5q31.1, and a GT dinucleotide repeat polymorphism has been described in its 7th intron. [7] [8] [9] In the present study we genotyped 574 MS patients and 527 healthy control subjects, sampled from three geographically separate European populations (Germany, Sweden and Northern Italy) for this polymorphism (Table 1) . Four common alleles were detected, corresponding to 11 (A1; 179 bp), 12 (A2; 181 bp), 16 (A6; 189 bp) and 17 (A7; 191 bp) GT dinucleotide repeats. Alleles corresponding to 13, 14 or 15 GT repeats (A3 → A5) were not identified in the Swedish and Italian populations. A3 was identified in the German population, albeit at a very low frequency (allele frequency of 0.003 in MS patients vs 0.008 in controls), and was therefore excluded from further analysis. Table 2 shows that in none of the three study populations, the global frequency of the four most common IRF1 alleles in MS patients deviated significantly from that in healthy control subjects. Neither did calculation of IRF1 GT phenotype and genotype frequencies, or stratification of German and Swedish patients according to the predisposing HLA DR2 alleles, reveal any significant disease association (data not shown). 23 Primer design and genotyping by means of an automated fluorescence sequencing system was performed as described. 9, 26 We next typed 139 Sardinian simplex MS families, each composed of two healthy parents and one affected child. In Sardinia, MS has been shown to be linked to the DRB1* 0405-DQA1*0501-DQB1*0301 and DRB1*0301-DQA1* 0501-DQB1*0201 HLA haplotypes, rather than to the more typical DRB1*1501-DQA1*0102-DQB1*0602 HLA haplotype which is associated with the disease all over continental Europe. 10, 11 Also, the Sardinian population is phylogenetically and ethnically more homogeneous than the continental European ones. 12 In such genetically isolated populations, linkage disequilibrium is likely to extend over a distance of several centimorgans from the susceptibility locus. 13 This implies that the effects of even minor susceptibility loci can be uncovered more easily
Genes and Immunity over a wider distance. Table 3 shows the results of a TDT on IRF1 GT alleles. However, no significant parental transmission distortion was observed. Stratification of affected children according to predisposing HLA haplotypes did not introduce any transmission bias (data not shown).
Our results demonstrate that IRF1 is not associated with MS in Europe. Similarly, the IRF1 GT dinucleotide repeat polymorphism appeared not to be associated with another autoimmune disease, ie, insulin-dependent diabetes mellitus, in a Danish population sample.
14 The IRF-1 gene has been mapped to the distal region of 5q, where it has been localized within the interleukin-3 (IL-3), IL-4, IL-5, IL-9, IL-13 and GM-CSF cluster of cytokine genes. 15 In a previous study, we have demonstrated that an IL-4 gene minisatellite polymorphism was not globally associated with susceptibility to MS in Sardinia and Northern Italy, although an association between the IL4*B1 allele and late onset of disease was observed. 16 Taken together, these results suggest that the 5q cytokine cluster is unlikely to impose any dramatic effects on the genetic risk for developing MS. This coincides with the findings of complete genome screenings on MS. With the exception of the American-French genome screen showing weak linkage (LOD score of 1.14) with a marker on chromosome 5q14.3, no evidence was found for any involvement of the distal part of the q arm of chromosome 5 in susceptibility to MS. 17 Further investigation is warranted to clarify whether other components of the interferon system may contribute to the genetic susceptibility for MS. Although the IFN-␣/␤ gene cluster has already been ruled out as a major candidate region in the Swedish 18 and Sardinian 19 populations, we 20, 21 and others 22 have provided evidence for association or linkage of the IFN-␥ locus with MS in the same populations. Research in the German population excluded the IFN-␤ gene as a candidate for MS predisposition, but suggested the existence of predisposing IFN-␣ genes. 23, 24 Furthermore, the family of interferon regulatory factors constitutes clearly a very interesting target for future studies, as some of its members are located within or near chromosomal regions exhibiting significant linkage to MS. To these belong IRF2 at 4q35.1, IRF3 at 19q13.3-13.4 and IRF4 at 6p23-25. Among these, the IRF2 locus in particular is worth further study, since enhanced expression of IRF-2 in acute MS lesions as compared to normal white matter was recently uncovered by means of cDNA microarray technology. Numbers of heterozygous parents who do or do not transmit the indicated IRF1 allele to the affected child. 
